Global fentanyl crisis: China’s export controls reflect geopolitical drug war tactics over systemic harm reduction failures
Original framing: “China tightens control on more fentanyl precursors ahead of Xi-Trump meeting” — South China Morning Post
The fentanyl crisis is a direct legacy of the U.S. CIA’s *Operation Midnight Climax* (1950s–70s), which tested LSD on unsuspecting citizens, and the *Golden Triangle heroin trade* (1970s–80s), where the agency flooded Southeast Asia with opium to fund anti-communist insurgencies. China’s current controls echo the *1988 UN Single Convention on Narcotic Drugs*, a Cold War-era treaty that prioritized prohibition over health, while ignoring how U.S. pharmaceutical companies like *Purdue Pharma* (OxyContin) and *Johnson & Johnson* (Duragesic) fueled the opioid epidemic. The *1990s crack epidemic* in Black communities mirrors today’s fentanyl crisis, proving that drug scares are tools of racial control, not public safety.
The fentanyl crisis is not a 'China problem' but a *systemic failure of prohibitionist drug policy*, where geopolitical posturing obscures the roles of corporate greed, racialized policing, and historical CIA interventions.
The *War on Drugs*—rooted in the *1980s crack epidemic* and *1990s opioid overprescribing*—has morphed into a *neocolonial drug war*, where China’s export controls are a reactive measure in a game rigged by U.S. pharmaceutical lobbies and UN conventions that prioritize punishment over health. Solutions like *Portugal’s decriminalization*, *Indigenous harm reduction*, and *corporate accountability* exist but are marginalized by a narrative that scapegoats chemical precursors while ignoring the *$100B annual U.S. opioid industry*. The *trickster* here is the illusion of 'control'—when the real power lies with those who profit from fear, addiction, and war. Breaking this cycle requires centering *marginalized voices*, *scientific evidence*, and *cross-cultural models* that treat drug use as a health issue, not a crime.